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Abstract
In this study, a novel scorpion venom-derived peptide named Gonearrestide was
identified in an in-house constructed scorpion venom library through a combination
of high-throughput NGS transcriptome and MS/MS proteome platform. In total, 238
novel peptides were discovered from two scorpion species; and 22 peptides were
selected for further study after a battery of functional prediction analysis. Following
a series of bioinformatics analysis alongside with in vitro biological functional
screenings, Gonearrestide was found to be a highly potent anticancer peptide which
acts on a broad spectrum of human cancer cells while causing few if any observed
cytotoxic effects on epithelial cells and erythrocytes. We further investigated the
precise anticancer mechanism of Gonearrestide by focusing on its effects on the
colorectal cancer cell line, HCT116. NGS RNA sequencing was employed to obtain
full gene expression profiles in HCT116 cells, cultured in the presence and absence
of Gonearrestide, to dissect signalling pathway differences. Taken together the
in vitro, in vivo and ex vivo validation studies, it was proven that Gonearrestide
could inhibit the growth of primary colon cancer cells and solid tumours by trigger-
ing cell cycle arrest in G1 phase through inhibition of cyclin-dependent kinases 4
(CDK4) and up-regulate the expression of cell cycle regulators/inhibitors—cyclin D3,
p27, and p21. Furthermore, prediction of signalling pathways and potential binding
sites used by Gonearrestide are also presented in this study.
K E YWORD S
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1 | INTRODUCTION
Cancer is the second most lethal disease in humans and traditional
synthetic chemicals used in chemotherapy and radio-therapeutic
chemicals have extremely high cytotoxicity and cause much collateral
damage to normal tissues.1,2 Many cancer cells can develop chemo-/
radio-resistance after a period of treatment.3,4 Hence, the quest for
new agents with lower cytotoxicity, fewer side-effects and a lowered
ability to induce drug resistance, has become an urgent goal for
modern cancer therapy. The advantages of employing peptide drugs
over conventional synthetic or semisynthetic organic chemicals are
their efficacy at low dosage, low toxicity, innocuous metabolites, aBin Li, and Peng Lyu are contributed equally to this work
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high capacity for structural modifications and high target speci-
ficity.5-8 Unlike most conventional chemotherapies, many anticancer
peptides have the capacity to specifically and selectively target can-
cer cells and they can also be used in combination with other anti-
cancer therapeutics, with which the observed synergistic effects
have been found to improve outcomes.9,10
Nature has always been a capable and predictable source of
remarkable pharmaceutical substances with potential usage for the
treatment of many diverse diseases. It has been proven that pep-
tides/proteins are generally the major components of venoms, and
many of these have either shown high potential or indeed had such
realised, to defeat diseases such as bacterial/fungal infections, car-
diovascular disorders, diabetes and cancers.11-13 However, less than
1% of the peptide/protein components of venoms have been well
studied at present.6 One of the reasons for this is due to the fact
that traditional proteomic approaches to address this problem are
slow. Recently, improvements in liquid chromatography-tandem mass
spectrometry (LC-MS/MS) have made it more accurate, sensitive and
amenable to high-throughput de novo sequencing of venom pep-
tidomes/proteomes.14-16 Also, the development of next-generation
DNA sequencing technology can also facilitate higher throughput in
this process and indeed is powerful enough and cost-efficient for
ultrahigh-throughput transcriptome analysis.17-21 Some venom
researchers have started to apply these two approaches, but erro-
neous assembly is a major limitation of next-generation sequencing
technology, while LC-MS/MS requires an existing database of struc-
tures to validate the de novo sequencing results.22-24 Hence, a high-
throughput platform combining transcriptome and proteome
sequencing was established in this study and employed successfully
to enable large-scale, high-throughput identification of novel bioac-
tive peptides in venoms.
Based on this platform, we have identified a panel of novel
potential anticancer peptides in scorpion venoms. Anticancer peptide
research has been performed at a low level for around 50 years now
with limited success and understanding of their mechanisms of
action is still in the initial stage. To reveal the potential anticancer
mechanisms of candidate peptide, a recently invented transcriptome-
centric strategy was employed to predict their putative functions
and targeted signalling pathways. Compared to traditional mechanis-
tic study approaches, this was able to monitor the collective
responses of all relevant genes without specific mechanistic or tar-
geting hypotheses.25-31 On the other hand, although the transcrip-
tome-centric approach has been applied in some research, the
enormous challenges in terms of data processing, storage and inter-
pretation as well as sequencing quality control have been huge limi-
tations which have hindered the translation from sequence data to
clinical practice, but a few studies have succeeded in proving the
concept.32-35 Hence, here, we performed related in vitro, in vivo and
ex vivo experiments to lend further substance to the validation of
this approach.
In this study, we initially isolated a panel of potential anticancer
peptides from venoms using this state-of-the-art high-throughput
platform. Subsequently, a transcriptome-centric method was applied
to address and to reveal the putative anticancer mechanism of the
lead peptide candidate, followed by in vitro, in vivo and ex vivo
experimental validation. In addition, we hypothesized as to the
involvement of specific signalling pathways and potential binding
sites through bioinformatic analyses and use of 3D modelling con-
struction software. Finally, one peptide candidate (Gonearrestide)
was identified to affect cancer cell proliferation in vitro and reduce
tumour growth in vivo, while negligible cytotoxicity was observed on
normal human epithelial cells and erythrocytes. These current data
suggest that Gonearrestide has a high potential for development as
an anticancer drug. In addition, the findings presented here have fur-
ther validated the ever-increasing potential of this high-throughput
platform and transcriptome-centric mechanistic study strategy to
reveal additional novel anticancer peptide drug candidates.
2 | MATERIALS AND METHODS
2.1 | Acquisition of scorpion venom
Venoms from the scorpions, Androctonus mauritanicus (AMa) and
Androctonus australis (Egypt) (AAu), were purchased from Latoxan,
Valence, France. The lyophilized venoms were stored at 20°C prior
to use.
2.2 | Transcriptomic procedures
Five mg sample from each lyophilized scorpion venom was dissolved
in 1 mL of cell lysis buffer (Thermo Fisher Scientific). Polyadenylated
mRNA was extracted by use of a Dynabeads mRNA DIRECTTM Kit
(Ambion by Life Tech), then subjected to a cDNA library construc-
tion procedure using a NEBNext UltraTM Directional RNA Library
Prep Kit for Illumina (New England BioLabs Inc.). According to the
instructions, the cDNA library construction consisted of several main
steps. First of all the mRNA fragmentation was achieved by incubat-
ing at 94°C with random primers. Then the RNA fragments were
subjected to first strand cDNA and second strand cDNA syntheses.
After purification with 1.8X Agencourt AMPure XP beads, end repair
of the cDNA library was performed by incubating with the end
repair reaction buffer and the nucleotide A was added to the 30 end
of the DNA fragments to avoid self- ligation. Therefore, the adapters
with the nucleotide T at the 30 end were ligated to the DNA frag-
ments. At last, the DNA fragments with adapters were enriched by
PCR reactions and purified by AMPure XP beads. The quality of the
cDNA library was verified using an Agilent 2100 Bioanalyzer (Agilent
Technologies) with an Agilent DNA 1000 kit (Agilent Technologies).
The quantity of the cDNA library was validated by qPCR with a
KAPA SYBR FAST qPCR kit (KAPA Biosystems). The cDNA library
was then loaded into a flow cell with oligos complementary to the
adapters to generate clusters through bridge amplification. Finally,
the transcriptome was obtained by performing RNA Sequencing on
the Illumina MiSeq platform. The raw data obtained from the Miseq
platform were analysed as follows. Firstly, the index primers used to
identify different samples were removed. Secondly, the data were
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transferred to the program FastQC 0.1.0.1 to filter out the reads
with low quality and less than 25 nucleotides. The filtered data were
saved as fastq files. At last, the clean reads were de novo assembled
using Trinity 2.0.6 software to obtain the transcriptome with default
parameters.
2.3 | Proteomic procedures
A second set of 5 mg lyophilized scorpion venom sample was dis-
solved in phosphate buffer (50 mmol/L, pH 7, containing 0.15 mol/L
NaCl), and subjected to AKTA Avant 150 (GE Healthcare Life
Science) fractionation using a Superose 12 10/300 GL column
(Sigma Aldrich) to filter out large proteins with molecular masses
higher than 10 KD. After this, Tris (2-chloroethyl) phosphate (TCEP)
was used to reduce disulphide bonds, and iodoacetamide (IAA) was
used to alkylate free cysteine residues. At last, desalting was per-
formed using PierceTM C18 Spin Tips (Thermo Scientific). Pro-
teomics was performed using the Q ExactiveTM Hybrid Quadrupole-
Orbitrap Mass Spectrometer (Thermo Scientific) with a nano-LC sys-
tem. Samples were loaded onto the Acclaim pepMap100,
75 lm 9 2 cm C18 trap column (Thermo Scientific) using LC-MS
water (containing 2% ACN, 0.1% formic acid). Samples were trapped
onto the column at 6 lL/min for 5 minutes for pre-concentration,
then the trap column was connected to an EASY-Spray column,
15 cm 9 75 lm ID, 3 lm-C18 particle sizes (Thermo Scientific) by a
10 port valve automatically. Eluting was performed at a flow rate of
300 nL/min with the gradient mobile phase buffer (Mobile phase
buffer A: LC-MS water, 2% ACN, and 0.1% formic acid; Mobile
phase buffer B: ACN, 2% LC-MS water and 0.1% formic acid). Elut-
ing peptide cations were converted to gas-phase ions by electro-
spray ionization with a spray voltage of 1.8 kV and capillary
temperature of 300°C. Full MS scans of peptide precursors from
300 to 1800 m/z were performed at 70 K resolution, while the AGC
target was set to 3 9 106 ion counts with a max injection time of
200 ms. MS2 was performed by an isolation window at 2 m/z with
the quadrupole, high energy collision (HCD) fragmentation with nor-
malized collision energy of 27. The resolution was 17.5 K, while ion
count target was set to 106 and the max injection time was 110 ms.
The top 20 precursor ions were selected in each cycle and only
those precursors with a charge state +2 to +5 were isolated for MS2
fragmentation. The fixed first mass of MS2 spectrum range started
at 100 m/z. The C-trap under fill ratio was 2%, which converted to
the intensity threshold of 1.7 9 104 for the precursor selection. The
dynamic exclusion duration was set to 20 seconds and isotope
exclusion was turned on. The LC-MS/MS raw data were then trans-
ferred to PEAKS (version7.5) software for de novo sequencing with
default parameters.
2.4 | Comparison between transcriptome and
proteome
The software, PEAKS (version8.0) (Bioinformatics Solutions Inc.,
Waterloo, ON, Canada), was used to interrogate the transcriptome
database with parameters set as: precursor ion mass tolerance,
3 ppm; fragment ion mass tolerance, 0.01 Da; no enzymes
employed; a variety of post-translational modifications (PTMs)
including cysteine carbamidomethylation and oxidation, were used
and false discovery rate (FDR) was at ≤1%. The peptides identified
high confidence and accuracy, constituted the prospective venom-
derived peptide libraries.
2.5 | Molecular cloning procedures
A third set of 5 mg lyophilized scorpion venom sample was dissolved
in 1 mL of cell lysis/mRNA protection buffer, and polyadenylated
mRNA was isolated from each by magnetic oligo-dT beads as
described by the manufacturer (Thermo Fisher Scientific). The iso-
lated mRNA was subjected to 50- and 30-rapid amplification of cDNA
ends (RACE) procedures using a SMART-RACE kit (Clontech, UK).
The 30-RACE reactions were purified and cloned using a TOPO TA
Cloning Kit (Invitrogen) and sequenced using an ABI 3100 auto-
mated sequencer. The nucleic acid sequences were isolated by
employing the primers below, which were designed to highly-con-
served domains of the 50-untranslated regions of previously-charac-
terized venom peptide cDNAs from scorpions: (i) Primer
AMa_Mauri1 (50-CATTACTATGTTGATTGTCGATGAAGTC-30); (ii) Pri-
mer AAm _H2 (50-AGTTTGGCACTTCTCTTCGTGAC-30); (iii) Primer
And_Uni1 (50-TAGWCCTGSTRGTYARTCCGA-30).
2.6 | Novel venom-derived peptide library
construction and peptide synthesis
The prospective novel venom-derived peptide libraries were sub-
jected to BLAST analyses against the NCBI non-redundant database
and the peptide sequences which produced hits with the sequences
on this were then subjected to Pfamscan online searching to identify
whether the sequences aligned to any reported toxins. The peptide
sequences reported before were removed manually during this step.
The novel peptides were manually filtered by removing very short
sequences and finally, the venom-derived peptide library was con-
structed with all the peptide sequences selected as above. The
selected peptide regions were chemically-synthesized by solid phase
peptide synthesis (SPPS) technology.
2.7 | Cell culture and potential anticancer peptide
screening
Cancer cell lines were maintained in their culture medium with 10%
(v/v) foetal bovine serum (FBS) and 1% (v/v) penicillin/streptomycin.
All cells were seeded into 75 cm2 culture flasks (Falcon, Fisher Sci-
entific), and cultured in an incubator under 5% CO2/95% air at
37°C. The anti-proliferative effects of these novel peptides on
human cancer cells were measured by employing MTT cell viability
assays. Peptides were screened at a concentration of 10 lmol/L
with various cell lines: Pancreatic cancer cell lines MIA Paca-2,
PANC-1, AsPC-1; Colon cancer cell lines HCT116, DLD-1, Hke3,
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Dks8; Breast cancer cell lines MCF-7, MDA-MB-231; Bladder can-
cer cell line HT-1376; Human retinal epithelial cancer cell line
ARPE-19; Brain glioma cell line U-251. Two different normal epithe-
lial human cell lines (colon cell line FHC and breast cell line MCF
10A) were also employed in the screening assays. Peptides with
anti-proliferative activities were then selected and further studied in
a dose-dependent manner in the concentration range from 250 to
1 lmol/L.
2.8 | Haemolysis assay
Human erythrocytes were washed with PBS until the supernatant
was clear, and then samples of a 4% (v/v) suspension were treated
with peptide concentrations ranging from 1 to 250 lmol/L at 37°C
for 1 hour. Lysis of cells was assessed by haemoglobin release, mea-
sured by optical density changes at k550 nm, and calculated com-
pared to positive controls. Positive control groups and negative
control groups were treated with equal volumes of Triton X-100 and
PBS instead of peptide, respectively.
2.9 | LDH assay
Cells were treated with different peptide concentrations from 250
to 10 lmol/L for 24 hours. LDH Cytotoxicity Assay Kit (Cayman,
USA) was then employed to detect the cytotoxicity of peptides
according to the manufacturer’s instructions. The supernatants were
transferred, mixed with the reaction buffer and LDH release was
detected using a microplate reader set at 492 nm and calculated
compared to positive controls. Positive control groups and negative
control groups were treated with equal volumes of Triton X-100 and
PBS instead of peptide, respectively.
2.10 | Apoptosis assay (phosphatidylserine
exstrophy detection)
Cells were treated with peptides at the concentration of 250 lmol/L
for 24 hours, after which the Alexa Fluor 488 annexin V/Dead Cell
Apoptosis Kit (Invitrogen) was employed to detect apoptosis accord-
ing to the manufacturer’s instructions along with use of a flow
cytometer BD AccuriTM C6. The blank control group was treated with
an equal volume of PBS.
2.11 | Proliferation curve generated through an
IncuCyte live cell imaging system
Cells were seeded into 6-well plates and treated with peptides at
250 lmol/L for 24 hours, after which the IncuCyte ZOOMTM Contin-
uous Live-cell Imaging & Analysis System was employed to record
cell growth for three days. The instrument can automatically gener-
ate cell growth curves, which are calculated by the cell area attached
to the bottom of each well according to the images taken by the
instrument every 2 hours. Blank control group was treated with
equal volumes of PBS.
2.12 | RNA sequencing reveals signalling pathways
altered by peptide treatment
Samples were prepared by treating cells with Gonearrestide at
250 lmol/L for 24 hours. Blank control groups and negative control
groups were treated with equal volumes of PBS and negative control
peptide, respectively. For each group, two replicates were employed.
Samples were collected and total RNA was extracted, DNA library
preparation was performed as previously described under “Transcrip-
tomics procedures”. Transcriptome sequencing and analysis procedures
were performed as follows: TruSeq RNA-seq libraries were sequenced
on the Illumina HiSeq2000 platform. The raw reads were mapped to the
human genome (version: GRCh38, ftp://ftp.ensembl.org/pub/release-
87/fasta/homo_sapiens/dna//Homo_sapiens.GRCh38.dna.primary_asse
mbly.fa.gz) using the splice aligner tophat2 (v2.1.1) with default parame-
ters.36 Gene expression analysis was performed using cuffdiff (v2.2.1)
from tuxedo pipeline.37 CummerBund 2 (v0.1.3, R package) from tuxedo
pipeline was used to normalize the data sets and calculate the fold
changes and their statistical significance on the basis of two indepen-
dent biological replicates for each set of conditions. Genes with fold
changes of 1.5 (log2fold change: absolute (0.6)) and q_value cut-off of
<0.05, were considered as significantly differentially expressed. Further
GO enrichment and pathway visualization of differentially expressed
genes was performed by the DAVID online tool (https://david.ncifc
rf.gov) and KEGG mapper (http://www.genome.jp/kegg/tool/map_path
way2.html), respectively.
2.13 | Detection of cell cycle status through use of
flow cytometry
Cells were treated with peptides at 250 lmol/L for 24 hours, after
which cells were collected and fixed with cold 70% ethanol over-
night. The next day, cells were washed with PBS and stained with
staining working solution (500 lL PBS containing 50 lg/mL PI,
100 lg/mL RNase A, and 0.2% Triton X-100) for 5 minutes at room
temperature. Density of cells in each cell cycle phase was recorded
by flow cytometry using a BD AccuriTM C6. The blank control group
was treated with an equal volume of PBS.
2.14 | Identification of involved proteins in the cell
cycle process through Western blotting
Cells were treated with peptides at 250 lmol/L for 24 hours. The
blank control group was treated with an equal volume of PBS, and
regarded as time-point 0 hour. Cells treated with peptides were then
collected at different time-points (treated after 2, 6, 12, 24, 48,
72 hours) and washed with cold PBS. RIPA buffer (150 mmol/L
NaCl, 5 mmol/L EDTA, 50 mmol/L Tris-HCl, 1% NP-40, 0.5%
sodium deoxycholate, 0.1%SDS) was used to lyse cells for 30 min-
utes on ice, after which cells were centrifuged at 20 0009 g for
another 30 minutes in a 4°C pre-cooled centrifuge. The supernatants
were stored at 80°C prior to use. Equal amounts of protein sam-
ples at each time-point, including those from the blank control
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group, were subjected to SDS-PAGE and then transferred to a mem-
brane. Membranes were then blocked with 5% non-fat dry milk in
TBST (0.1% Tween) for 2 hour at room temperature, and then incu-
bated with primary antibodies (against Cyclin D1, Cyclin D3, CDK2,
CDK4, CDK6, p18, p21, p27) at 4°C overnight. The next day, TBST
(0.1% Tween) was used to wash membranes three times, after which
secondary HRP conjugated antimouse/anti-rabbit antibody was incu-
bated with membranes for 1 hour at room temperature. After wash-
ing with TBST (0.1% Tween) another three times, Immobilon
Western HRP Substrate was employed for chemiluminescent detec-
tion in Western blots.
2.15 | Characterization of cellular location of
peptide through use of confocal microscopy
Cells were cultured in an 8-chamber slide and treated with fluores-
cently labelled peptides for 1 hour. After this, cells were stained with
CellMask Plasma Membrane Stains (Invitrogen) and Hoechst dye
(Thermo Fisher) according to the manufacturer’s instructions, fol-
lowed by washing with PBS and fixation with 3.75% formaldehyde.
The locations of peptides affecting cells were recorded by confocal
laser scanning microscopy.
2.16 | In vivo anticancer activity of the peptide
Nude Mice used in this study were obtained from the Animal Facility
in the Faculty of Health Sciences at the University of Macau (UM).
All the experimental protocols were conducted according to the UM
Ethics Committee for Animal Experiments with the approved applica-
tion UMARE-035-2016.
In vivo anticancer activity of Gonearrestide was evaluated in an
HCT116 colon cancer xenograft model. 1 x 106 HCT116 colon can-
cer cells were xenotransplanted by subcutaneous injection (s. c.) into
the flanks of 4 week-old female nude mice. After 3 days of implan-
tation, mice were then divided into four groups: Group 1 (n = 5) was
treated with Gonearrestide at a high concentration (100 lg/tumour)
by peritumoral (p. t.) injection for another 2 weeks; Group 2 (n = 5)
was treated with Gonearrestide at low concentration (50 lg/tumour)
while Groups 3 and 4 (n = 5) were treated with an equal volume of
PBS and negative control peptide, respectively. Tumour volume mea-
surement was performed during 2 weeks of treatment. To determine
tumour volume by use of an external caliper, the greatest longitudi-
nal diameter (length) and the greatest transverse diameter (width)
were determined. Tumour volumes, based on caliper measurements,
were calculated by the modified ellipsoidal formula38,39: Tumour vol-
ume = 1/2(length 9 width2). At the end of the experiment, tumours
were removed under anaesthesia and mice were then euthanized.
Tumours were snap-frozen for further histological analysis. On the
one hand, tumours were fixed and cut into slides. Immunohisto-
chemical staining of tumour slides were performed by de-paraffiniz-
ing in xylene and rehydrating in graded ethanol, followed by
incubation in sodium citrate buffer (pH 6.0) for high-pressure antigen
retrieval. Afterwards, slides were incubated in 3% hydrogen peroxide
to block endogenous peroxidase activity, and incubated with cell
cycle checkpoint antibody CDK4 at 4°C overnight. On the second
day, the slides were incubated with secondary antibody and sub-
jected to diaminobenzidine staining. After counterstaining with 20%
haematoxylin, slides were dehydrated and mounted on cover slips.
The IHC-stained tissue sections were reviewed under a microscope.
In addition, mRNA and proteins were isolated from frozen tumours
for qPCR and Western blot analysis. The procedures were for both
techniques were described before.
2.17 | Statistical analysis
Statistical analysis was performed using GraphPad Prism 6 software.
P values were calculated by student’s t-test from the mean values of
the indicated data. Significant differences were marked with aster-
isks (*P < .05; **P < .01; ***P < .001; ****P < .0001).
3 | RESULTS
3.1 | Novel venom-derived peptide library
construction through combining transcriptome and
proteome analyses
3.1.1 | RNA sequencing with next-generation
sequencing technology
In total, there were 514 974 and 625, 389 raw reads generated for
the scorpion species, Androctonus mauritanicus (AMa) and Androc-
tonus australis (Egypt) (AAu), respectively. As these two scorpion spe-
cies do not have their genomes assembled so far, the transcriptome
data were de novo assembled by use of Trinity software. Conse-
quently, there were 112 235 and 46 360 nucleic acid sequences,
respectively, obtained for each species (Table 1A). The transcripts
were saved as Fastq files (S1 and 2).
3.1.2 | Isolation and de novo sequencing of
proteomes through use of a highly accurate and
sensitive LC-MS/MS system
The raw spectra generated from the AMa venom contained 20 606
peptides fragments. After alignment, the remaining 9225 peptide
fragments obtained were filtered with the filtration parameter set-
ting of an average local confidence of more than 50%. The de novo
sequencing results including 3346 peptide fragments were saved as
Excel files (S3; Table 1A). Similarly, from the AAu venom, we identi-
fied 2393 different peptide fragments after filtered from 7464 pep-
tide fragments (S4; Table 1A).
3.1.3 | Comparison between respective
transcriptomes and proteomes
In AMa transcriptome and proteome analysis, there were 1176
peptide fragments in the overlapping region between transcriptome
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and proteome databases for the two species, which aligned to 128
peptides (Table 1A). With the same method, 110 peptides were
aligned from 924 peptide fragments in AAu transcriptome and pro-
teome analysis (Table 1A). The overlapping peptides were regarded
as the prospective venom-derived peptide libraries and saved as
Excel files (S5).
To further validate our findings, we also compared AMa and AAu
proteomes with an online scorpion protein database (UniProt). In
total, there were 130 peptides matched with UniProt database,
which indicated the robustness of our data.
3.1.4 | Molecular cloning
There were eight peptide sequences isolated through the molecular
cloning approach, including three novel peptide sequences. All
these eight peptide sequences were found in the overlapping
region of the transcriptome and the proteome results, which vali-
dated the new high-throughput approach. The nucleotide and
translated open-reading frames of the three novel sequences were
saved (Figure S1).
3.1.5 | Novel venom-derived peptide library
construction and peptide synthesis
The overlapping regions described previously were subjected to a
variety of bioinformatic analyses and the filtered results were saved
(Figure S2). As a result, novel venom-derived peptide libraries with
41 and 30 peptides were obtained for scorpion species AMa and
AAu, respectively (S5). Twenty-two peptide sequences were initially
selected to synthesize for use in further analyses (Table S1).
3.2 | Biological functional screening of the
synthesized peptides
3.2.1 | Cell anti-proliferative assay
In total, 22 peptides were screened with 19 cell lines to identify
their potential anti-proliferative activities, after which four peptides
(Peptides 4, 6, 10 and 13) were found to inhibit the proliferation of
human colon cancer cell lines HCT116, DLD-1, Hke3, Dks8 and the
human glioma cell line U-251. Two types of normal human epithelial
cell lines, including the colon cell line FHC and the breast cell line
MCF 10A, were also employed here and it was found that the pep-
tides had negligible effects on their proliferation even at highest
concentrations. Peptide 13 (Gonearrestide, the amino acid sequence
was shown in Table S1) was found to have the most potent activity
on human colon cancer cell line HCT116, thus it was chosen as a
lead peptide for further investigation. The does-dependent anti-pro-
liferation effect of Gonearrestide was shown in Figure 1A.
3.2.2 | Haemolysis assay
This demonstrated that Gonearrestide had negligible cytotoxicity on
human erythrocytes with a haemolytic activity below 5% (positive
control was regarded as 100%), indicating that Gonearrestide was a
worthy candidate for further study with the view to its clinic applica-
tion (Figure 1B).
3.3 | Biological functions validation of
Gonearrestide in vitro
3.3.1 | LDH assay
Lactate dehydrogenase (LDH) is released when cell membrane integ-
rity is compromised. In this assay, Gonearrestide did not induce LDH
release from HCT116 cells after 24 hours of incubation. This result
indicated that Gonearrestide did not disrupt the cell membrane and
did not induce cell death. At the same time, the LDH results were
consistent with the RNA sequencing data along with the combina-
tion of MTT results. Taken together, these data confirmed that
TABLE 1 (A) Summary of Transcriptome and Proteome data.
(B) Summary of up and down-regulated genes between each group
in RNA sequencing data of HCT116 cells treated with/without
Gonearrestide
(A)
Scorpion species
Androctonus
mauritanicus
Androctonus
australis (Egypt)
Transcriptome de novo assemble
Raw reads 514 974 625 389
Nucleic acids
sequences
112 235 46 360
Proteome de novo sequencing
Spectrums 20 606 16 205
Peptide
fragments
9225 7464
Filtered peptide
fragmentsa
3346 2393
Comparison between Transcriptome and Proteome
Database Scorpion Transcriptome Scorpion Transcriptome
Spectrums 872 3398 646 2516
Peptide
fragments
351 1176 267 924
Peptides 67 128 63 110
(B)
Comparison
Up-regulated
genes
Down-regulated
genes
HCT116_BC vs
HCT116_Gonearrestide
1906 2032
HCT116_NC vs
HCT116_Gonearrestide
1835 2510
HCT116_BC vs HCT116_NC Not significant Not significant
aFiltration parameter: ALC (average local confidence) > 50%.
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Gonearrestide affected cancer cell proliferation through inhibition of
growth (Figure 1C).
3.3.2 | Determination of cellular location of peptide
through use of confocal microscopy
We further investigated the cellular location of Gonearrestide by
incubating FITC-labelled Gonearrestide (250 lmol/L) with HCT116.
Localization of Gonearrestide within the cell should result in green
fluorescence signals from the FITC-labelled peptide. As shown in Fig-
ure 1D, Gonearrestide treated HCT116 cells showed strong green
fluorescence signal on the cell membrane of HCT116. In contrast
with the normal human epithelial cell group, there was almost no sig-
nal detected. In another set of control experiment, we also found
that incubation of negative peptide to HCT116 cell lines did not
show green fluorescent in the cell membrane at all. These data
clearly indicated that Gonearrestide was specifically localized on the
cancer cell membrane only. On the other hand, green fluorescence
signal was not detected in cytoplasm or nuclear of the cell, suggest-
ing that Gonearrestide did not enter into the cell compartments.
Taken together, it demonstrated that Gonearrestide was specifically
bound to the cancer cell membrane, and induced subsequent
reactions via membrane-related signalling pathways which will fur-
ther be hypothesized and analysed in our “cell-peptide” RNA
sequencing experiments.
3.3.3 | Apoptosis assay (Phosphatidylserine
exstrophy detection)
Annexin V and PI staining along with flow cytometry can differenti-
ate individual cells into different stages. The results of these experi-
ments were shown in Figure 1E. The data showed that
Gonearrestide did not induce apoptosis of HCT116 cells when com-
pared to blank controls—a finding which was also consistent with
our RNA sequencing data in this study.
3.3.4 | Proliferation curve generated through
IncuCyte live cell imaging system
As shown in Figure 1F, the proliferation of HCT116 cells treated
with Gonearrestide was much slower than that observed for the
blank controls. The results proved that Gonearrestide could inhibit
cancer cell growth which again was consistent with our RNA
sequencing data in this study.
F IGURE 1 Anti-proliferative of Gonearrestide. A, Dose-dependent anti-proliferative effects of Gonearrestide treated on human cancer cell
lines HCT116 and human normal cell lines MCF10A, FHC after 24 h of incubation (n = 15). The growth inhibition of cells at each peptide
concentration was calculated as a percentage of the growth observed in controls, which was treated as 100%. B, Haemolytic activity of
Gonearrestide with gradient concentrations on human red blood cells. Haemolysis was calculated as a percentage compared with positive
control (add Triton X-100), which was treated as positive control (n = 15). C, LDH release of Gonearrestide with gradient concentrations on
cancer cell HCT116. LDH release was calculated as a percentage compared with positive control (add Triton X-100), which was treated as
100% (n = 15). D, Cellular location of FITC-labelled peptide binding on human cell lines. (Confocal microscope with 63X/oil magnification) E,
Apoptosis result of Gonearrestide on HCT116 using flow cytometry. Blank control group was cells without adding peptide. F, Inhibition effect
of Gonearrestide working on human colon cancer cell line HCT116 generated by IncuCyte live cell imaging system. Blank control group was
cells treated with equal amount of PBS (n = 15)
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3.4 | RNA sequencing revealed the biological
function and signalling pathways altered by peptide
treatment
As Gonearrestide had the best activity on the cancer cell line
HCT116 with no obvious cytotoxicity on normal human cell lines
and erythrocytes, it was chosen for further experiments to identify
its molecular mechanism of action. There were three groups
employed in this assay: HCT116 treated with Gonearrestide
(HCT116_Gonearrestide), HCT116 treated with a negative control
peptide (HCT116_NC) and HCT116 treated with PBS (HCT116_BC).
The negative control peptide was one of the previously identified
peptides which showed no anticancer cell activity.
Approximately 40 million reads were generated per sample and
around 90% of these were aligned to the human genome with a cor-
relation value of 0.9 between and across replicates (Figure S3). The
top 500 variable genes (based on standard deviation) demonstrated
that the replicates were consistent but slight differences were pre-
sent between the blank control and the negative peptide groups
(Figure S4). Genes were determined as being significantly differen-
tially expressed (DEG) based on a twofold log change and a q-value
cut-off of absolute (0.6) and 0.05, respectively (S6). After filtration
with the fold change and statistical significance, the remaining signif-
icantly differentially expressed genes were shown in Table 1B. There
were around 2000 genes up- or down-regulated after Gonearrestide
treatment, while the differences between the blank control and neg-
ative peptide groups were not significant. From the comparison of
the HCT116_BC vs the HCT116_Gonearrestide data sets and the
HCT116_NC vs the HCT116_Gonearrestide data sets, 1416 common
genes were found to be up-regulated, while 1637 common genes
were down-regulated (Figure 2A and B). The top 10 pathways (P
value < .05, tool: DAVID) enriched under common genes (1416,
1637) have been listed (Figure 2C and D).
As shown in Figure 2C, the up-regulated functions and pathways
included proteoglycans in cancer, focal adhesion, MAPK signalling
pathway and dysregulated pathways included spliceosome, RNA
transport and ribosome. Ribosome biogenesis in eukaryotes, plays an
important role in cell proliferation.40-47 On the other hand, the PI3K-
Akt signalling pathway, cell cycle, DNA replication, pyrimidine meta-
bolism and purine metabolism, are all closely related to cell cycle
progression. Hence, we hypothesized that Gonearrestide could affect
the proliferation of HCT116 cancer cells through cell cycle arrest
effects. Heat maps of cell cycle-related genes and cell cycle check-
point control-relevant pathways were generated and shown in
Figure 3D and 3E. As most of the pathways annotated to the func-
tions of cell proliferation and cell cycle, in vitro and in vivo biological
assays were then employed to verify the hypothesis. In addition, cur-
rent results showed that peptide treatment did not cause cell death
or apoptosis, so LDH and apoptosis assays were also employed to
validate the hypothesis from another point of view. In addition, there
were still some other functions and pathways involved of note as
shown in Figure 2C, such as phagosome, endocytosis and lysosome,
which are all related to membrane reactions. Hence, we
hypothesized that Gonearrestide worked through initial combination
with cancer cell membranes, then produced subsequent effects.
Based on this, confocal imaging experiments were designed and con-
ducted as described in Figure 1D.
3.5 | In vitro cell cycle arrest effect on
Gonearrestide
3.5.1 | Detection of cell cycle phase through flow
cytometry
Cell cycle phase distribution of HCT116 cells treated with/without
Gonearrestide was shown in Figure 3A and B. These data demon-
strated that Gonearrestide arrested cancer cell cycle in G1 phase,
and was consistent with our findings in Figure 2D which showed
the cell cycle signals were actually down-regulated after Gonear-
restide treatment.
3.5.2 | Identification of proteins involved in cell
cycle processes by Western blotting
As Gonearrestide could arrest HCT116 cells in G1 phase, G1/S
checkpoint protein antibodies were employed to identify the regula-
tory proteins involved, including cyclin D1, cyclin D3, CDK2, CDK4,
CDK6, p18, p21 and p27. Western blot results are shown in Fig-
ure 3C, and the data demonstrated that Gonearrestide worked
through inhibiting the cyclin-dependent kinase 4 (CDK4), and up-reg-
ulating the expression of the cell cycle protein regulators/inhibitors,
cyclin D3, p27, p21. These results were again consistent with the
RNA sequencing data and also matched with our predicted pathways.
3.6 | In vivo anticancer activity validation of
Gonearrestide
The xenograft mouse model was employed to verify the robustness
of the in vitro results. The data of resultant tumour volume with or
without peptide treatments were shown in Figure 4A. The volume
of implanted tumours was significantly reduced in a dose-dependent
manner of Gonearrestide. The negative peptide control group did
not show any significance differences. These results confirmed that
Gonearrestide could exert its anticancer activity in vivo. All mice
were sacrificed at the end of the experiment and tumours were
removed for further analysis (Figure 4B). The qPCR and Western
blot data from the tumour tissues also showed that Gonearrestide
could regulate cell cycle checkpoint proteins in vivo, and the trend
was consistent with the in vivo results (Figure 4C and D). Immuno-
histochemical staining was also performed and showed that Gonear-
restide could down-regulate CDK4 in vivo as shown in Figure 4E.
3.7 | Prediction of signalling pathways involved
Through combination of RNA sequencing data and biological
in vitro/in vivo results, we hypothesized the signalling pathways
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involved in cell cycle progression, which were shown in Figure 5A.
We believed that after Gonearrestide bound with the cancer cell
membrane, cationic Gonearrestide could affect PIP3 by electrostatic
attraction to its anionic trisphosphate group, resulting in the inhibi-
tion of the Akt pathway. PTEN, a lipid phosphatase that catalyses
the dephosphorylation of PIP3 to produce PIP2, is a major negative
regulator of Akt signalling. The inhibition of Akt was followed by the
up-regulation of FOXO1/3, GSK-3b and p21, inducing the dysregula-
tion of CDK4/6 and CDK2. The decline in CDK4/6 and CDK2 would
inhibit the phosphorylation of retinoblastoma (RB) protein, which
could release the transcription factor, E2F/DP, from the RB-E2F/DP
complexes, thereby promoting cells entry from G1 to S phase.
Among all these genes, p27, p21, cyclin D3 and CDK4/6 were evalu-
ated through Western blot assays, which further proved this
prediction. On the other hand, after bioinformatics analysis, a series
of biomarkers involved in peptide treatment related to colon cancer
were also identified (Figure S5).
3.8 | Hypothesis of potential binding site
It has been reported that phosphatidylserine (PS) and phos-
phatidylethanolamine (PE) can enhance membrane poration by a
peptide with anticancer properties.48 As a lipid, PIP3 displays a simi-
lar 2D structure to PS and PE (Figure 5 B, C and D). Hence we
hypothesized that Gonearrestide could bind to PIP3, resulting in the
following reactions. Docking between the peptide and the lipid was
performed to prove the concept through using C-DOCKER in soft-
ware Discovery Studio 2017 (Figure 5E). The 3D structure of PIP3
F IGURE 2 Comparison results and function/pathway annotation of HCT116_BC vs HCT116_Gonearrestide set and HCT116_NC vs
HCT116_Gonearrestide set. A, Up-regulated genes. B, Down-regulated genes. C, Top 10 up-regulated pathways. D, Top 10 down-regulated
pathways
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was constructed by homology modelling, and the 3D structure of
PIP3 was transformed from the 2D structure downloaded from Pub-
chem. The 2D diagram of peptide-lipid interaction was shown in
Figure 5F. From the diagram, it demonstrated that the residues W1,
K12 and K14 presented a charge attracting effect with PIP3, which
further proved our hypothesis in Gonearrestide affects on PIP3 via
electrostatic attraction to its anionic trisphosphate group.
4 | DISCUSSION
Venom from animals has been proven to be a useful source of drug
candidates in natural drug discovery to fight against diseases.49,50
Especially for venom-based peptide/toxin, it has been paved new
insights into therapeutic and diagnostic potential for cancer treat-
ment in the last decade.51-56 In a leading edge review on cancer
research by Hanahan and Weinberg, authors discussed six important
hallmarks of cancer; and proposed an ideal anticancer drug should
able to inhibit and/or block one or several cancer hallmarks.57
Recent studies have unveiled the interaction of venom peptides
with some membrane receptor molecules, non-receptor compo-
nents, and/or extracellular matrix which could induce cancer hall-
mark dysregulation or inhibition.57 For instance, NN-32, a protein
toxin purified from Naja naja venom exerted a cytotoxic activity on
MCF-7 and MDA-MB-231 cells, and thereby induced cancer cell
death directly.51 Another examples, WEV and sPLA2, isolated from
F IGURE 3 Cell cycle assay results. A, Cell cycle phase distribution of Gonearrestide on human colon cancer cell line HCT116 after 24 h of
incubation using flow cytometry. B, Calculated percentage of cells in each phase (n = 9). C, Cell cycle-related proteins regulated by
Gonearrestide on HCT116. Time-point “0 h” was blank control group treated with equal amount of PBS. D, Heat map of cell cycle-related
genes. E, Cell cycle checkpoint control-related pathways (yellow indicating up-regulated genes and red indicating down-regulated genes)
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F IGURE 4 In vivo anticancer activity of Gonearrestide on HCT116 xenograft model (n = 5). A, Tumour volume growth curve after peptide
treatment. B, Mice tumour tissues after sacrifice. C, Relative fold change of cell cycle-related genes regulated by Gonearrestide on mice
tumour. The levels of significance are: *P < .05; **P < .01; ***P < .001; ****P < .001. D, Western blot results of cell cycle checkpoints
proteins regulated by Gonearrestide on mice tumour. E, Immunohistochemical analysis of paraffin-embedded mice tumour tissue sections using
cell cycle checkpoints antibody CDK4 (1:100), noted that CDK4 was dysregulated
F IGURE 5 Predicted signalling pathways and potential binding site. A, Predicted signalling pathways involved in cell cycle progress of colon
cancer HCT116 treated with Gonearrestide. Noted that the regulated genes were identified by RNA-seq, among which p27, p21, CDK4/6 and
Cyclin D3 were evaluated by Western bolt. B-D, 2D structures of PS, PE and PIP3. E, Peptide-lipid interactions between Gonearrestide and
PIP3 lipid molecular generated through C-DOCKER. F, 2D diagram of the peptide-lipid interaction, which shows the electrostatic interaction
between Gonearrestide and PIP3
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snake venom from Walterinnesia aegyptia and Vipera ammodytes
meriodionalis, respectively, induced apoptosis on a broad spectrum
of cancer cell lines.52-55 Furthermore, the combination of WEV and
silica nanoparticles efficiently enhanced the in vivo suppressive
effect in mouse models.52-54
To increase the identification of potential venom-sourced anti-
cancer peptides, a high efficiency and low-cost screening platform is
urgently required. In this study, a high-throughput screening platform
consisting of transcriptome and proteome sequencing is described
and has been of proven efficacy. Based on the use of this platform,
complete peptide libraries of venoms from the scorpions, Androc-
tonus mauritanicus (AMa) and Androctonus australis (Egypt) (AAu),
have been constructed. To confirm the validity of this platform, a
traditional cloning approach was also applied in parallel. The tradi-
tionally-derived cloning data provided evidence of the robust nature
of the described high-throughput screening platform. The coupling
of transcriptomic and proteomic/peptidomic approaches using bioin-
formatics produced venom-derived peptide panels, which could be
used to explore the potential therapeutically useful peptides present
in respective venoms.58
Within the scorpion peptide panels, bioinformatics filtration and
MTT screening were initially applied to detect novel candidate anti-
cancer peptides. As a result, peptide 13(Gonearrestide) was identi-
fied and found to have a potent anticancer activity against human
colon cancer cell line HCT116 but with negligible observed cytotoxi-
city against normal human epithelial cells and erythrocytes. To study
the anticancer mechanisms of Gonearrestide, RNA sequencing was
used to detect the transcriptome responses in cells following Gon-
earrestide treatment. Transcriptome sequencing provided a number
of advantages over conventional chemical screening strategies. This
approach did not require prior identification of specific drug targets.
This meant that, based on a multi-target, pathway-centric approach,
any potential therapeutic targets could be assessed in the transcrip-
tome landscape. Compared with phenotypic screening, transcriptome
screening offers more specific gene expression responses providing
crucial clues to potential molecular mechanisms.32 Thus, this
approach was a powerful strategy to study the mechanisms of
venom-derived anticancer peptide drug actions.
The RNA sequencing results indicated that Gonearrestide could
combine with cancer cell membranes followed by inhibition of cell
proliferation through a cell cycle arrest effect. Although well-
designed in vitro, in vivo and ex vivo assays, the transcriptome-cen-
tric prediction that Gonearrestide could arrest HCT116 cancer cells
in G1 phase and inhibit tumour growth, was proven. The signalling
pathway used involved effects on PIP3 and PTEN, resulting in the
inhibition of the Akt pathway. PIP3 is a phospholipid that is bound
within the layers of the cell membrane and after combining with the
cell membrane, Gonearrestide can affect PIP3 by electrostatic attrac-
tion to its anionic trisphosphate group. PTEN catalyses the dephos-
phorylation of PIP3 to produce PIP2, which is a major negative
regulator of Akt signalling. It is a tumour suppressor and the phos-
phatase activity of this protein may also be related to cell cycle regu-
lation preventing cells growing and dividing too rapidly. From the
previous anti-proliferative screening results, it could also be seen
that Gonearrestide showed a better anticancer effect on the PTEN
wild-type cell line, HCT116, when compared with the PTEN-mutated
cell lines, PC-3 and SW872, with cell viabilities of 55%, 84% and
80%, respectively. The inhibition of Akt induced downstream dysreg-
ulation of CDK4/6 and CDK2, thereby promoting cell entry from G1
to S phase. In addition, the peptide-lipid interaction generated by
docking also proved the hypothesis that Gonearrestide could bind to
PIP3 through electrostatic attraction and resulted in alerting the
downstream cell cycle regulation.
Current results showed that Gonearrestide could inhibit cell pro-
liferation in vitro through a cell cycle arrest effect and could reduce
tumour growth in vivo, while possessing little observable cytotoxicity
on human epithelial cells and erythrocytes. Hence, this peptide was
deemed to have a great potential to be proceed to clinical trials as
an anticancer drug candidate. To enhance the efficiency of anti-
cancer peptide discovery, we emphasize the broad utility of our
high-throughput platform for venom-derived peptide library con-
struction and selection and also the interfacing of this with a tran-
scriptome-centric mechanistic study approach. The validity of this
approach has been proven by well-designed experiments described
and employed in this study. Moreover, within the scorpion peptide
panel, several additional anticancer peptides are awaiting further
investigation.
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